Active Filters

  • (-) PSI Authors = Schibli, Roger
  • (-) Journals ≠ Applied Radiation and Isotopes
Search Results 1 - 20 of 223

Pages

  • RSS Feed
Select Page
Terbium-149 production: a focus on yield and quality improvement towards preclinical application
Favaretto, C., Grundler, P. V., Talip, Z., Köster, U., Johnston, K., Busslinger, S. D., … van der Meulen, N. P. (2024). Terbium-149 production: a focus on yield and quality improvement towards preclinical application. Scientific Reports, 14(1), 3284 (12 pp.). https://doi.org/10.1038/s41598-024-53610-2
First-in-human administration of terbium-161-labelled somatostatin receptor subtype 2 antagonist ([<sup>161</sup>Tb]Tb-DOTA-LM3) in a patient with a metastatic neuroendocrine tumour of the ileum
Fricke, J., Westerbergh, F., McDougall, L., Favaretto, C., Christ, E., Nicolas, G. P., … Wild, D. (2024). First-in-human administration of terbium-161-labelled somatostatin receptor subtype 2 antagonist ([161Tb]Tb-DOTA-LM3) in a patient with a metastatic neuroendocrine tumour of the ileum. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-024-06641-w
Relaxed fibronectin: a potential novel target for imaging endometriotic lesions
Trachsel, B., Imobersteg, S., Valpreda, G., Singer, G., Grabherr, R., Ormos, M., … Béhé, M. (2024). Relaxed fibronectin: a potential novel target for imaging endometriotic lesions. EJNMMI Research, 14(1), 17 (11 pp.). https://doi.org/10.1186/s13550-024-01070-0
A tool for nuclear imaging of the SARS-CoV-2 entry receptor: molecular model and preclinical development of ACE2-selective radiopeptides
Beyer, D., Vaccarin, C., Deupi, X., Mapanao, A. K., Cohrs, S., Sozzi-Guo, F., … Müller, C. (2023). A tool for nuclear imaging of the SARS-CoV-2 entry receptor: molecular model and preclinical development of ACE2-selective radiopeptides. EJNMMI Research, 13(1), 32 (14 pp.). https://doi.org/10.1186/s13550-023-00979-2
Investigations using albumin binders to modify the tissue distribution profile of radiopharmaceuticals exemplified with folate radioconjugates
Busslinger, S. D., Becker, A. E., Vaccarin, C., Deberle, L. M., Renz, M. L., Groehn, V., … Müller, C. (2023). Investigations using albumin binders to modify the tissue distribution profile of radiopharmaceuticals exemplified with folate radioconjugates. Cancers, 15(17), 4259 (19 pp.). https://doi.org/10.3390/cancers15174259
<sup>161</sup>Tb-DOTATOC production using a fully automated disposable cassette system: a first step toward the introduction of <sup>161</sup>Tb into the clinic
Favaretto, C., Grundler, P. V., Talip, Z., Landolt, S., Sepini, L., Köster, U., … van der Meulen, N. P. (2023). 161Tb-DOTATOC production using a fully automated disposable cassette system: a first step toward the introduction of 161Tb into the clinic. Journal of Nuclear Medicine, 64(7), 1138-1144. https://doi.org/10.2967/jnumed.122.265268
Targeting mTORC1 activity to improve efficacy of radioligand therapy in cancer
Grzmil, M., Wiesmann, F., Schibli, R., & Behe, M. (2023). Targeting mTORC1 activity to improve efficacy of radioligand therapy in cancer. Cancers, 15(1), 17 (12 pp.). https://doi.org/10.3390/cancers15010017
Detecting radio- and chemoresistant cells in 3D cancer co-cultures using chromatin biomarkers
Pekeč, T., Venkatachalapathy, S., Shim, A. R., Paysan, D., Grzmil, M., Schibli, R., … Shivashankar, G. V. (2023). Detecting radio- and chemoresistant cells in 3D cancer co-cultures using chromatin biomarkers. Scientific Reports, 13(1), 20662 (14 pp.). https://doi.org/10.1038/s41598-023-47287-2
Signaling network response to <em>α</em>-particle–targeted therapy with the <sup>225</sup>Ac-labeled minigastrin analog <sup>225</sup>Ac-PP-F11N reveals the radiosensitizing potential of histone deacetylase inhibitors
Qin, Y., Imobersteg, S., Frank, S., Blanc, A., Chiorazzo, T., Berger, P., … Grzmil, M. (2023). Signaling network response to α-particle–targeted therapy with the 225Ac-labeled minigastrin analog 225Ac-PP-F11N reveals the radiosensitizing potential of histone deacetylase inhibitors. Journal of Nuclear Medicine, 64(6), 873-879. https://doi.org/10.2967/jnumed.122.264597
Reducing kidney uptake of radiolabelled exendin-4 using variants of the renally cleavable linker MVK
Trachsel, B., Valpreda, G., Lutz, A., Schibli, R., Mu, L., & Béhé, M. (2023). Reducing kidney uptake of radiolabelled exendin-4 using variants of the renally cleavable linker MVK. EJNMMI Radiopharmacy and Chemistry, 8(1), 21 (11 pp.). https://doi.org/10.1186/s41181-023-00206-2
Albumin-binding and conventional PSMA ligands in combination with <sup>161</sup>Tb: biodistribution, dosimetry, and preclinical therapy
Tschan, V. J., Busslinger, S. D., Bernhardt, P., Grundler, P. V., Zeevaart, J. R., Köster, U., … Müller, C. (2023). Albumin-binding and conventional PSMA ligands in combination with 161Tb: biodistribution, dosimetry, and preclinical therapy. Journal of Nuclear Medicine, 64(10), 1625-1631. https://doi.org/10.2967/jnumed.123.265524
Inductively coupled plasma mass spectrometry - a valid method for the characterization of metal conjugates in view of the development of radiopharmaceuticals
Wallimann, R. H., Schindler, P., Hensinger, H., Tschan, V. J., Busslinger, S. D., Kneuer, R., … Schibli, R. (2023). Inductively coupled plasma mass spectrometry - a valid method for the characterization of metal conjugates in view of the development of radiopharmaceuticals. Molecular Pharmaceutics, 20(4), 2150-2158. https://doi.org/10.1021/acs.molpharmaceut.2c01092
Design and evaluation of novel albumin-binding folate radioconjugates: systematic approach of varying the linker entities
Benešová, M., Guzik, P., Deberle, L. M., Busslinger, S. D., Landolt, T., Schibli, R., & Müller, C. (2022). Design and evaluation of novel albumin-binding folate radioconjugates: systematic approach of varying the linker entities. Molecular Pharmaceutics, 19, 963-973. https://doi.org/10.1021/acs.molpharmaceut.1c00932
Combination of terbium-161 with somatostatin receptor antagonists - a potential paradigm shift for the treatment of neuroendocrine neoplasms
Borgna, F., Haller, S., Monné Rodriguez, J. M., Ginj, M., Grundler, P. V., Zeevaart, J. R., … Müller, C. (2022). Combination of terbium-161 with somatostatin receptor antagonists - a potential paradigm shift for the treatment of neuroendocrine neoplasms. European Journal of Nuclear Medicine and Molecular Imaging, 49, 1113-1126. https://doi.org/10.1007/s00259-021-05564-0
Preclinical investigations to explore the difference between the diastereomers [<sup>177</sup>Lu]Lu-SibuDAB and [<sup>177</sup>Lu]Lu-RibuDAB toward prostate cancer therapy
Borgna, F., Deberle, L. M., Busslinger, S. D., Tschan, V. J., Walde, L. M., Becker, A. E., … Müller, C. (2022). Preclinical investigations to explore the difference between the diastereomers [177Lu]Lu-SibuDAB and [177Lu]Lu-RibuDAB toward prostate cancer therapy. Molecular Pharmaceutics, 19(7), 2105-2114. https://doi.org/10.1021/acs.molpharmaceut.1c00994
[<sup>225</sup>Ac]Ac-SibuDAB for targeted alpha therapy of prostate cancer: preclinical evaluation and comparison with [<sup>225</sup>Ac]Ac-PSMA-617
Busslinger, S. D., Tschan, V. J., Richard, O. K., Talip, Z., Schibli, R., & Müller, C. (2022). [225Ac]Ac-SibuDAB for targeted alpha therapy of prostate cancer: preclinical evaluation and comparison with [225Ac]Ac-PSMA-617. Cancers, 14(22), 5651 (16 pp.). https://doi.org/10.3390/cancers14225651
IMPACT conceptual design report
Eichler, R., Kiselev, D., Koschik, A., Knecht, A., van der Meulen, N., Scheibl, R., … Züllig, J. (2022). IMPACT conceptual design report. (PSI Bericht, Report No.: 22-01). Paul Scherrer Institut.
Comparative analysis of cancer cell responses to targeted radionuclide therapy (TRT) and external beam radiotherapy (EBRT)
Grzmil, M., Boersema, P., Sharma, A., Blanc, A., Imobersteg, S., Pruschy, M., … Behe, M. (2022). Comparative analysis of cancer cell responses to targeted radionuclide therapy (TRT) and external beam radiotherapy (EBRT). Journal of Hematology & Oncology, 15(1), 123 (5 pp.). https://doi.org/10.1186/s13045-022-01343-y
Implementing subtype-specific pre-clinical models of breast cancer to study pre-treatment aspirin effects
Miller, I. S., Khan, S., Shiels, L. P., Das, S., O' Farrell, A. C., Connor, K., … Byrne, A. T. (2022). Implementing subtype-specific pre-clinical models of breast cancer to study pre-treatment aspirin effects. Cancer Medicine, 11(20), 3820-3836. https://doi.org/10.1002/cam4.4756
Impact of the mouse model and molar amount of injected ligand on the tissue distribution profile of PSMA radioligands
Tschan, V. J., Borgna, F., Schibli, R., & Müller, C. (2022). Impact of the mouse model and molar amount of injected ligand on the tissue distribution profile of PSMA radioligands. European Journal of Nuclear Medicine and Molecular Imaging, 49, 470-480. https://doi.org/10.1007/s00259-021-05446-5
 

Pages